Terazosin Capsule
Product Images NDC 50090-7851

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 50090-7851). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 01)

Chemical structure diagram of terazosin hydrochloride dihydrate (C19H25N5O4 · HCl · 2H2O) with a molecular weight of 459.93. The structure includes a piperazine ring, methoxy groups, and additional functional groups as shown.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 02)

A clinical study data table comparing terazosin and placebo effects on symptom score and peak flow rate across three studies with different dosages and durations. The table includes participant numbers, mean baseline scores, and mean change percentages for symptom scores and peak flow rates, indicating statistically significant improvements with terazosin versus placebo.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 03)

This figure, titled 'Study 1,' contains two line graphs comparing terazosin and placebo groups over 3 months. The left graph shows mean change in total symptom score from baseline, with terazosin demonstrating a greater reduction. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with terazosin showing a higher increase compared to placebo.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 04)

A line graph titled 'Mean Change in Total Symptom Score from Baseline' depicting data from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents time in months (0 to 30), and the y-axis shows the mean change from baseline in symptom scores, ranging from 0 to -7. Data points with error bars are plotted, showing a decrease in symptom score over time with significance indicated by asterisks at multiple time points compared to baseline.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 05)

A line graph titled 'Mean Change in Peak Flow Rate from Baseline' showing data from a long-term, open-label, non-placebo controlled study with 494 participants. The graph plots mean change from baseline in mL/sec on the vertical axis against months on the horizontal axis, ranging from 0 to 30 months. Two lines with error bars are shown, indicating statistically significant changes at various time points.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 06)

A data table presenting mean changes in systolic (SBP) and diastolic blood pressure (DBP) from baseline to final visit in double-blind placebo-controlled studies. It compares placebo and terazosin groups across normotensive (DBP ≤ 90 mmHg) and hypertensive (DBP > 90 mmHg) patients, including sample sizes (N) and mean changes in mmHg. Significant differences versus placebo are indicated.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 07)

A data table titled 'Adverse Reactions During Placebo-Controlled Trials Benign Prostatic Hyperplasia' comparing adverse reactions by body system between terazosin (N=636) and placebo (N=360) groups. The table lists percentages of various symptoms such as asthenia, dizziness, postural hypotension, and impotence among others, with statistical significance indications noted for some differences.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 08)

Table presenting discontinuation rates during placebo-controlled trials for benign prostatic hyperplasia. It compares terazosin and placebo groups across various body systems including Body as a Whole, Cardiovascular, Digestive, Nervous, Respiratory, Special Senses, and Urogenital systems, listing specific adverse events with corresponding percentages for each treatment group.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 09)

Data table titled 'Table 3 Adverse Reactions During Placebo-Controlled Trials Hypertension' showing the frequency of adverse reactions by body system for terazosin (N=859) versus placebo (N=506). It categorizes reactions across various systems, including body as a whole, cardiovascular, digestive, metabolic, musculoskeletal, nervous, respiratory, special senses, and urogenital, with corresponding percentage values for terazosin and placebo groups. Statistically significant differences at p=0.05 are indicated.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 10)

A table titled 'Discontinuation During Placebo-Controlled Trials Hypertension' comparing percentage rates of discontinuation by body system between terazosin (N=859) and placebo (N=506). It lists body systems with specific symptoms under each, showing higher discontinuation percentages for terazosin versus placebo across categories such as body as a whole, cardiovascular system, digestive system, metabolic and nutritional disorders, nervous system, respiratory system, and special senses.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 12)

FDA Label Image

Label Image (Lbl500907851)

Terazosin 1 mg oral capsules label from A-S Medication Solutions. The label includes the drug's active ingredient, terazosin hydrochloride USP equivalent to 1 mg terazosin per capsule, storage instructions to keep between 68 to 77 degrees Fahrenheit away from light and moisture, and specifies a package of 30 capsules. It features the product number, NDC 50090-7851-0, and barcode information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.